Key Highlights
- EyePoint Pharmaceuticals shares plunged 67% to $4.87.
- The Phase 3 LUGANO trial evaluating DURAVYU in wet AMD failed to meet its primary BCVA endpoint.
- An ad hoc analysis excluding nine patients with unrelated vision loss demonstrated non-inferiority to aflibercept.
- The market now awaits LUCIA data in Q4 2026 and a potential NDA submission in the first half of 2027.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares plunged 67% to $4.87 after the company announced that its Phase 3 LUGANO trial evaluating DURAVYU in wet age-related macular degeneration failed to meet its primary best-corrected visual acuity endpoint.
What Happened
An ad hoc analysis excluding nine patients with unrelated vision loss demonstrated non-inferiority to aflibercept, alongside a 42% reduction in treatment burden and favorable safety.
Market Reaction
Shares plunged sharply as investors focused on the primary endpoint miss in the full dataset, despite the more favorable results in the ad hoc analysis excluding unrelated vision-loss patients.
Outlook
The market awaits LUCIA data in the fourth quarter of 2026 and a potential NDA submission in the first half of 2027, both of which represent the next major disclosed milestones for DURAVYU in wet AMD.
FAQs
Q: Why did EyePoint Pharmaceuticals shares plunge 67%?
A: Shares fell after the company's Phase 3 LUGANO trial for DURAVYU failed to meet its primary BCVA endpoint in wet AMD.
Q: Did any part of the data show positive results?
A: Yes, an ad hoc analysis excluding nine patients with unrelated vision loss showed non-inferiority to aflibercept, a 42% reduction in treatment burden, and favorable safety.
Q: What is the next milestone for DURAVYU?
A: LUCIA data expected in the fourth quarter of 2026, ahead of a potential NDA submission in the first half of 2027.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.